Home・Aandelen Lijst・Moderna Inc

Moderna Inc

Gesloten

SectorGezondheidszorg

63.15 -0.71

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

60.62

Max

63.76

Belangrijke statistieken
By Trading Economics
Inkomsten	561M -782M
Verkoop	-244M 145M
EPS	-1.97
Winstmarge	-539.31
Werknemers	4,700
EBITDA	554M -704M

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	-22.74% downside

Dividenden
By Acuity
Volgende Winsten	5 nov 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	1.8B 24B
Vorige openingsprijs	63.86
Vorige sluitingsprijs	63.15

Nieuwssentiment

By Acuity

50%

163 / 340 Rangschikking in Healthcare

Moderna Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 aug 2026, 23:51 UTC

Social Media

Moderna shares are lower in after-market hours amid concerns over the FDA's approval of its mRNA flu vaccine and modest trial data effectiveness.

13 aug 2026, 23:21 UTC

Social Media

Moderna's first mRNA flu shot receives FDA approval, despite concerns over a high adverse reaction rate. Shares are higher in after-market trading.

12 aug 2026, 23:51 UTC

Moderna Inc shares are lower in after-market hours with no specific news identified. Recent easing inflation has influenced broader market sentiment.

10 aug 2026, 19:36 UTC

Social Media

The FDA has approved Moderna's mRNA flu vaccine for adults 50 and older. Shares are advancing modestly amid concerns over safety and efficacy.

7 aug 2026, 19:52 UTC

Social Media

The FDA approved Moderna's mRNA flu vaccine, mFlusiva, for adults 50 and older. Shares are higher during Friday's trading session.

6 aug 2026, 23:06 UTC

Social Media

Moderna's mRNA flu vaccine, "mFlusiva," receives FDA approval for adults aged 50 to 64, boosting shares higher in after-market trading.

5 aug 2026, 19:46 UTC

Social Media

Event

Moderna Inc. shares are lower as disappointing ADP employment data weighs on market sentiment. The FDA has set a decision date for its mFlusiva vaccine.

4 aug 2026, 20:07 UTC

Social Media

News

Moderna initiates Phase 1 trial for mRNA-1469 vaccine, backed by CEPI's $50 million funding. Shares are higher despite earlier session pullback.

3 aug 2026, 20:03 UTC

News

Moderna Inc. shares are advancing as Citigroup raises its price target to $60 amid broader market strength and gains in major tech stocks.

31 jul 2026, 23:26 UTC

Moderna Inc. shares are lower in after-hours trading, continuing a decline from Friday's close without any specific news to explain the movement.

30 jul 2026, 23:51 UTC

Moderna Inc shares are higher in after-market trading, driven by a significant advance in the overall market, despite earlier fluctuations during the session.

29 jul 2026, 23:51 UTC

Moderna Inc is rising in after-market trading, aligning with broader market gains. The stock showed volatility earlier in the session without specific news driving the move.

28 jul 2026, 18:36 UTC

Moderna Inc shares are lower today, continuing a decline from Monday's close amid risk-off sentiment following significant declines in Asian markets.

27 jul 2026, 19:07 UTC

Social Media

Moderna Inc. is advancing as it initiates a Phase 1 trial for its mRNA-4200 cancer vaccine, with the first U.S. participant dosed on July 16, 2026.

24 jul 2026, 19:03 UTC

Social Media

News

Moderna Inc shares are lower today amid mixed options sentiment and increased demand for downside protection ahead of its upcoming earnings report.

23 jul 2026, 19:56 UTC

Social Media

News

Moderna Inc shares are lower, trading around $57.25, as options activity remains light. An mRNA vaccine is set for a Phase 1 trial in August.

21 jul 2026, 20:07 UTC

News

Social Media

Goldman Sachs raised Moderna's price target to $49.00 while maintaining a Neutral rating, reflecting a more favorable outlook on the company's valuation. Shares are higher today.

20 jul 2026, 23:46 UTC

Moderna Inc shares are lower in after-market hours amid rising Treasury yields and broader market trends, with no specific company news identified.

Peer Vergelijking

Prijswijziging

Moderna Inc Prognose

Koersdoel

By TipRanks

-22.74% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 48.92 USD -22.74%

Hoogste 77 USD

Laagste 39 USD

Gebaseerd op 15 Wall Street-analisten die 12-maands prijsdoelen bieden voor Moderna Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

15 ratings

Buy

Hold

Sell

Gebaseerd op 15 analisten die aandelenratings hebben gegeven aan Moderna Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

163 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Moderna Inc

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.